Abstract
Colony Stimulating Factor-1 (CSF-1)/Colony Stimulating Factor-1 Receptor (CSF-1R) signaling axis plays an essential role in the development, maintenance, and proliferation of macrophage lineage cells. Within the central nervous system, CSF-1R signaling primarily maintains microglial homeostasis. Microglia, being the resident macrophage and first responder to any neurological insults, plays critical importance in overall health of the human brain. Aberrant and sustained activation of microglia along with continued proliferation and release of neurotoxic proinflammatory cytokines have been reported in various neurological and neurodegenerative diseases. Therefore, halting the neuroinflammatory pathway via targeting microglial proliferation, which depends on CSF-1R signaling, has emerged as a potential therapeutic target for neurological disorders. However, apart from regulating the microglial function, recently it has been discovered that CSF-1R has much broader role in central nervous system. These findings limit the therapeutic utility of CSF-1R inhibitors but also highlight the need for a complete understanding of CSF-1R function within the central nervous system. Moreover, it has been found that selective inhibitors of CSF-1R may be more efficient in avoiding non-specific targeting and associated side effects. Short-term depletion of microglial population in diseased conditions have also been found to be beneficial; however, the dose and therapeutic window for optimum effects may need to be standardized further.
This review summarizes the present understanding of CSF-1R function within the central nervous system. We discuss the CSF-1R signaling in the context of microglia function, crosstalk between microglia and astroglia, and regulation of neuronal cell function. We also discuss a few of the neurological disorders with a focus on the utility of CSF-1R inhibitors as potential therapeutic strategy for halting the progression of neurological diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FMV (2007) Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 10:1538–1543. https://doi.org/10.1038/nn2014
Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, de Groot M, Quail DF, Tillard L, Gadiot J, Huse JT, Brandsma D, Westerga J, Watts C, Joyce JA (2020) Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aaw7843
Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM (2017) Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncol 19:796–807. https://doi.org/10.1093/neuonc/now287
Azouvi P, Arnould A, Dromer E, Vallat-Azouvi C (2017) Neuropsychology of traumatic brain injury: an expert overview. Rev Neurol (paris) 173:461–472. https://doi.org/10.1016/j.neurol.2017.07.006
Barcia C (2013) Glial-mediated inflammation underlying parkinsonism. Scientifica 2013:357805. https://doi.org/10.1155/2013/357805
Beckmann N, Giorgetti E, Neuhaus A, Zurbruegg S, Accart N, Smith P, Perdoux J, Perrot L, Nash M, Desrayaud S, Wipfli P, Frieauff W, Shimshek DR (2018) Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945. Acta Neuropathol Commun 6:9. https://doi.org/10.1186/s40478-018-0510-8
Benner B, Good L, Quiroga D, Schultz TE, Kassem M, Carson WE, Cherian MA, Sardesai S, Wesolowski R (2020) Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development. Drug Des Devel Ther 14:1693–1704. https://doi.org/10.2147/DDDT.S253232
Berezovskaya O, Maysinger D, Fedoroff S (1996) Colony stimulating factor-1 potentiates neuronal survival in cerebral cortex ischemic lesion. Acta Neuropathol (berl) 92:479–486. https://doi.org/10.1007/s004010050550
Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254–265. https://doi.org/10.1002/path.1027
Block ML, Zecca L, Hong J-S (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69. https://doi.org/10.1038/nrn2038
Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S (2009) Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer’s disease. Brain J Neurol 132:1078–1092. https://doi.org/10.1093/brain/awn331
Borjini N, Fernández M, Giardino L, Calzà L (2016) Cytokine and chemokine alterations in tissue, CSF, and plasma in early presymptomatic phase of experimental allergic encephalomyelitis (EAE), in a rat model of multiple sclerosis. J Neuroinflammation 13:291. https://doi.org/10.1186/s12974-016-0757-6
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M (2016) Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncol 18:557–564. https://doi.org/10.1093/neuonc/nov245
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M (2015) Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncol 18:557–564. https://doi.org/10.1093/neuonc/nov245
Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJG, Reynolds R, Martin R (2015) Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 16:147–158. https://doi.org/10.1038/nrn3900
Carroll JA, Race B, Williams K, Striebel J, Chesebro B (2020) RNA-seq and network analysis reveal unique glial gene expression signatures during prion infection. Mol Brain 13:71. https://doi.org/10.1186/s13041-020-00610-8
Casali BT, MacPherson KP, Reed-Geaghan EG, Landreth GE (2020) Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis 142:104956. https://doi.org/10.1016/j.nbd.2020.104956
Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease. Disease 56:484–546. https://doi.org/10.1016/j.disamonth.2010.06.001
Cherry JD, Tripodis Y, Alvarez VE, Huber B, Kiernan PT, Daneshvar DH, Mez J, Montenigro PH, Solomon TM, Alosco ML, Stern RA, McKee AC, Stein TD (2016) Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun. https://doi.org/10.1186/s40478-016-0382-8
Chitu V, Gokhan Ş, Nandi S, Mehler MF, Stanley ER (2016) Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends Neurosci 39:378–393
Chitu V, Pixley FJ, Macaluso F, Larson DR, Condeelis J, Yeung Y-G, Stanley ER (2005) The PCH family member MAYP/PSTPIP2 directly regulates F-actin bundling and enhances filopodia formation and motility in macrophages. Mol Biol Cell 16:2947–2959
Cioce M, Canino C, Goparaju C, Yang H, Carbone M, Pass HI (2014) Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis 5:e1167–e1167
Clayton K, Delpech JC, Herron S, Saito T, Ikezu S, Saido TC, Ikezu T (2020) CSF1R inhibitor abrogates tau propagation exacerbated in APPNL-G-F knock-in mice but enhances fibrillar beta-amyloidosis and dystrophic neurite formation in the brain. Alzheimers Dement 16:e040958. https://doi.org/10.1002/alz.040958
Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, Segall JE (2012) Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med Camb Mass 18:519–527. https://doi.org/10.2119/molmed.2011.00217
Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, Johnson JH, Frick L, Lin M-HJ, Depee S, Tadepalli S, Votta B, James I, Fuller K, Chambers TJ, Kull FC, Chamberlain SD, Hutchins JT (2005) Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A 102:16078–16083. https://doi.org/10.1073/pnas.0502000102
Conway JG, Pink H, Bergquist ML, Han B, Depee S, Tadepalli S, Lin P, Crumrine RC, Binz J, Clark RL, Selph JL, Stimpson SA, Hutchins JT, Chamberlain SD, Brodie TA (2008) Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther 326:41–50. https://doi.org/10.1124/jpet.107.129429
Coughlin JM, Wang Y, Minn I, Bienko N, Ambinder EB, Xu X, Peters ME, Dougherty JW, Vranesic M, Koo SM, Ahn H-H, Lee M, Cottrell C, Sair HI, Sawa A, Munro CA, Nowinski CJ, Dannals RF, Lyketsos CG, Kassiou M, Smith G, Caffo B, Mori S, Guilarte TR, Pomper MG (2017) Imaging of glial cell activation and white matter integrity in brains of active and recently retired national football league players. JAMA Neurol 74:67–74. https://doi.org/10.1001/jamaneurol.2016.3764
Coughlin JM, Wang Y, Munro CA, Ma S, Yue C, Chen S, Airan R, Kim PK, Adams AV, Garcia C, Higgs C, Sair HI, Sawa A, Smith G, Lyketsos CG, Caffo B, Kassiou M, Guilarte TR, Pomper MG (2015) Neuroinflammation and brain atrophy in former NFL players: an in vivo multimodal imaging pilot study. Neurobiol Dis 74:58–65. https://doi.org/10.1016/j.nbd.2014.10.019
Csar XF, Wilson NJ, McMahon K-A, Marks DC, Beecroft TL, Ward AC, Whitty GA, Kanangasundarum V, Hamilton JA (2001) Proteomic Analysis of Macrophage Differentiation p46/52Shc TYROSINE PHOSPHORYLATION IS REQUIRED FOR CSF-1-MEDIATED MACROPHAGE DIFFERENTIATION. J Biol Chem 276:26211–26217
Cui W, Allen ND, Skynner M, Gusterson B, Clark AJ (2001) Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia 34:272–282. https://doi.org/10.1002/glia.1061
Dai X-M, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER (2002) Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99:111–120
Daria A, Colombo A, Llovera G, Hampel H, Willem M, Liesz A, Haass C, Tahirovic S (2017) Young microglia restore amyloid plaque clearance of aged microglia. EMBO J 36:583–603
Dorababu A (2019) Critical evaluation of current Alzheimer’s drug discovery (2018–19) & futuristic Alzheimer drug model approach. Bioorganic Chem 93:103299. https://doi.org/10.1016/j.bioorg.2019.103299
Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674–677. https://doi.org/10.1126/science.1156995
Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 4:e7258. https://doi.org/10.1371/journal.pone.0007258
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26:756–784. https://doi.org/10.1101/gad.187922.112
Elixiron closes $27M series A for Alzheimer’s and vitiligo clinical trials [WWW Document], n.d. . FierceBiotech. URL https://www.fiercebiotech.com/biotech/elixiron-closes-27m-series-a-for-alzheimer-s-and-vitiligo-clinical-trials. Accessed 27 Aug 2021
Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL (2014) Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82:380–397
Elmore MRP, Lee RJ, West BL, Green KN (2015) Characterizing newly repopulated microglia in the adult mouse: impacts on animal behavior, cell morphology, and neuroinflammation. PLoS ONE 10:e0122912. https://doi.org/10.1371/journal.pone.0122912
Endele M, Loeffler D, Kokkaliaris KD, Hilsenbeck O, Skylaki S, Hoppe PS, Schambach A, Stanley ER, Schroeder T (2017) CSF-1–induced Src signaling can instruct monocytic lineage choice. Blood J Am Soc Hematol 129:1691–1701
Erblich B, Zhu L, Etgen AM, Dobrenis K, Pollard JW (2011) Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS ONE 6:e26317
Feng X, Liu S, Chen D, Rosi S, Gupta N (2018) Rescue of cognitive function following fractionated brain irradiation in a novel preclinical glioma model. Elife. https://doi.org/10.7554/eLife.38865
Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD (2007) Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol 178:5245–5252
Foucher ED, Blanchard S, Preisser L, Garo E, Ifrah N, Guardiola P, Delneste Y, Jeannin P (2013) IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. Antagonistic effects of GM-CSF and IFNγ. PLoS ONE 8:e56045
Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK, Foust KD, Godbout JP, Popovich PG, Guttridge DC, Kaspar BK (2014) Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron 81:1009–1023. https://doi.org/10.1016/j.neuron.2014.01.013
Galanis A, Levis M (2015) Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica 100:e77–e79. https://doi.org/10.3324/haematol.2014.117028
Gao H-M, Liu B, Zhang W, Hong J-S (2003) Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci 24:395–401
Garceau V, Smith J, Paton IR, Davey M, Fares MA, Sester DP, Burt DW, Hume DA (2010) Pivotal advance: avian colony-stimulating factor 1 (CSF-1), interleukin-34 (IL-34), and CSF-1 receptor genes and gene products. J Leukoc Biol 87:753–764
Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan XD, Ge T, Franks C, Greenspan A (2015) Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. J Rheumatol 42:1752–1760. https://doi.org/10.3899/jrheum.141580
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330:841–845. https://doi.org/10.1126/science.1194637
Goh LK, Sorkin A (2013) Endocytosis of receptor tyrosine kinases. Cold Spring Harb Perspect Biol 5:017459
Gómez-Nicola D, Fransen NL, Suzzi S, Perry VH (2013) Regulation of microglial proliferation during chronic neurodegeneration. J Neurosci 33:2481–2493. https://doi.org/10.1523/JNEUROSCI.4440-12.2013
Gowing G, Lalancette-Hébert M, Audet J-N, Dequen F, Julien J-P (2009) Macrophage colony stimulating factor (M-CSF) exacerbates ALS disease in a mouse model through altered responses of microglia expressing mutant superoxide dismutase. Exp Neurol 220:267–275. https://doi.org/10.1016/j.expneurol.2009.08.021
Hama H, Hara C, Yamaguchi K, Miyawaki A (2004) PKC signaling mediates global enhancement of excitatory synaptogenesis in neurons triggered by local contact with astrocytes. Neuron 41:405–415. https://doi.org/10.1016/s0896-6273(04)00007-8
Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42:781–785. https://doi.org/10.1038/ng.642
Han D, Dong X, Zheng D, Nao J (2020) MiR-124 and the underlying therapeutic promise of neurodegenerative disorders. Front Pharmacol. https://doi.org/10.3389/fphar.2019.01555
Hartong DT, Berson EL, Dryja TP (2006) Retinitis Pigmentosa. Lancet Lond Engl 368:1795–1809. https://doi.org/10.1016/S0140-6736(06)69740-7
He J, Zhao C, Dai J, Weng CH, Bian BSJ, Gong Y, Ge L, Fang Y, Liu H, Xu H, Yin ZQ (2019) Microglia mediate synaptic material clearance at the early stage of rats with retinitis pigmentosa. Front Immunol. https://doi.org/10.3389/fimmu.2019.00912
Hellwig S, Masuch A, Nestel S, Katzmarski N, Meyer-Luehmann M, Biber K (2015) Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-β plaque formation in organotypic hippocampal slice cultures. Sci Rep 5:14624. https://doi.org/10.1038/srep14624
Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19:610–621. https://doi.org/10.1038/s41583-018-0055-7
Henry RJ, Ritzel RM, Barrett JP, Doran SJ, Jiao Y, Leach JB, Szeto GL, Wu J, Stoica BA, Faden AI, Loane DJ (2020) Microglial depletion with CSF1R inhibitor during chronic phase of experimental traumatic brain injury reduces neurodegeneration and neurological deficits. J Neurosci 40:2960–2974. https://doi.org/10.1523/JNEUROSCI.2402-19.2020
Hickman SE, Allison EK, Khoury JE (2008) Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci 28:8354–8360. https://doi.org/10.1523/JNEUROSCI.0616-08.2008
Hilla AM, Diekmann H, Fischer D (2017) Microglia are irrelevant for neuronal degeneration and axon regeneration after acute injury. J Neurosci 37:6113–6124. https://doi.org/10.1523/JNEUROSCI.0584-17.2017
Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397
Ho MS (2019) Microglia in Parkinson’s disease. In: Verkhratsky A, Ho MS, Zorec R, Parpura V (eds) Neuroglia in neurodegenerative diseases, advances in experimental medicine and biology. Springer, Singapore, pp 335–353
Hoenen C, Gustin A, Birck C, Kirchmeyer M, Beaume N, Felten P, Grandbarbe L, Heuschling P, Heurtaux T (2016) Alpha-Synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS ONE 11:e0162717. https://doi.org/10.1371/journal.pone.0162717
Hou L, Zhou X, Zhang C, Wang K, Liu X, Che Y, Sun F, Li H, Wang Q, Zhang D, Hong J-S (2017) NADPH oxidase-derived H2O2 mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinson’s disease. Redox Biol 12:162–170. https://doi.org/10.1016/j.redox.2017.02.016
Hume DA, MacDonald K (2012) Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119:1810–1820
Huynh J, Kwa MQ, Cook AD, Hamilton JA, Scholz GM (2012) CSF-1 receptor signalling from endosomes mediates the sustained activation of Erk1/2 and Akt in macrophages. Cell Signal 24:1753–1761
Imai Y, Kohsaka S (2002) Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia 40:164–174. https://doi.org/10.1002/glia.10149
Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol (berl) 106:518–526. https://doi.org/10.1007/s00401-003-0766-2
Jha MK, Jo M, Kim J-H, Suk K (2019) Microglia-astrocyte crosstalk: an intimate molecular conversation. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 25:227–240. https://doi.org/10.1177/1073858418783959
Jha MK, Lee S, Park DH, Kook H, Park K-G, Lee I-K, Suk K (2015) Diverse functional roles of lipocalin-2 in the central nervous system. Neurosci Biobehav Rev 49:135–156. https://doi.org/10.1016/j.neubiorev.2014.12.006
Jo M, Kim J-H, Song GJ, Seo M, Hwang EM, Suk K (2017) Astrocytic orosomucoid-2 modulates microglial activation and neuroinflammation. J Neurosci 37:2878–2894. https://doi.org/10.1523/JNEUROSCI.2534-16.2017
Junttila I, Bourette RP, Rohrschneider LR, Silvennoinen O (2003) M-CSF induced differentiation of myeloid precursor cells involves activation of PKC-δ and expression of Pkare. J Leukoc Biol 73:281–288
Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T (2015) Retinal microglia: just bystander or target for therapy? Prog Retin Eye Res 45:30–57. https://doi.org/10.1016/j.preteyeres.2014.11.004
Kheir WA, Gevrey J-C, Yamaguchi H, Isaac B, Cox D (2005) A WAVE2-Abi1 complex mediates CSF-1-induced F-actin-rich membrane protrusions and migration in macrophages. J Cell Sci 118:5369–5379. https://doi.org/10.1242/jcs.02638
Kim J-H, Ko P-W, Lee H-W, Jeong J-Y, Lee M-G, Kim J-H, Lee W-H, Yu R, Oh W-J, Suk K (2017) Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementia. Glia 65:1471–1490. https://doi.org/10.1002/glia.23174
Klein D, Patzkó Á, Schreiber D, van Hauwermeiren A, Baier M, Groh J, West BL, Martini R (2015) Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot–Marie–Tooth disease in mice. Brain 138:3193–3205. https://doi.org/10.1093/brain/awv240
Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216:15–24. https://doi.org/10.1002/path.2370
Lamb YN (2019) Pexidartinib: first approval. Drugs 79:1805–1812. https://doi.org/10.1007/s40265-019-01210-0
Lampron A, Larochelle A, Laflamme N, Préfontaine P, Plante M-M, Sánchez MG, Yong VW, Stys PK, Tremblay M-È, Rivest S (2015) Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med 212:481–495. https://doi.org/10.1084/jem.20141656
Lei F, Cui N, Zhou C, Chodosh J, Vavvas DG, Paschalis EI (2020) CSF1R inhibition by a small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the function of macrophages. Proc Natl Acad Sci U S A 117:23336–23338. https://doi.org/10.1073/pnas.1922788117
Li E, Hristova K (2010) Receptor tyrosine kinase transmembrane domains: function, dimer structure and dimerization energetics. Cell Adhes Migr 4:249–254
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Münch AE, Chung W-S, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487. https://doi.org/10.1038/nature21029
Liu H, Leo C, Chen X, Wong BR, Williams LT, Lin H, He X (2012) The mechanism of shared but distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1. Biochim Biophys Acta BBA-Proteins Proteomics 1824:938–945
Loane DJ, Faden AI (2010) Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 31:596–604. https://doi.org/10.1016/j.tips.2010.09.005
Luo J, Elwood F, Britschgi M, Villeda S, Zhang H, Ding Z, Zhu L, Alabsi H, Getachew R, Narasimhan R, Wabl R, Fainberg N, James ML, Wong G, Relton J, Gambhir SS, Pollard JW, Wyss-Coray T (2013) Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J Exp Med 210:157–172. https://doi.org/10.1084/jem.20120412
Ma MW, Wang J, Dhandapani KM, Brann DW (2017) NADPH oxidase 2 regulates NLRP3 inflammasome activation in the brain after traumatic brain injury [WWW Document]. Oxid Med Cell Longev. https://doi.org/10.1155/2017/6057609
Ma X, Lin WY, Chen Y, Stawicki S, Mukhyala K, Wu Y, Martin F, Bazan JF, Starovasnik MA (2012) Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R. Structure 20:676–687
Majbour NK, Vaikath NN, Eusebi P, Chiasserini D, Ardah M, Varghese S, Haque ME, Tokuda T, Auinger P, Calabresi P, Parnetti L, El-Agnaf OMA (2016) Longitudinal changes in CSF alpha-synuclein species reflect Parkinson’s disease progression. Mov Disord 31:1535–1542. https://doi.org/10.1002/mds.26754
Mancuso R, Fryatt G, Cleal M, Obst J, Pipi E, Monzón-Sandoval J, Ribe E, Winchester L, Webber C, Nevado A, Jacobs T, Austin N, Theunis C, Grauwen K, Daniela Ruiz E, Mudher A, Vicente-Rodriguez M, Parker CA, Simmons C, Cash D, Richardson J, NIMA Consortium, Jones DNC, Lovestone S, Gómez-Nicola D, Perry VH (2019) CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain J. Neurol. 142:3243–3264. https://doi.org/10.1093/brain/awz241
Mangale V, Syage AR, Ekiz HA, Skinner DD, Cheng Y, Stone CL, Brown RM, O’Connell RM, Green KN, Lane TE (2020) Microglia influence host defense, disease, and repair following murine coronavirus infection of the central nervous system. Glia. https://doi.org/10.1002/glia.23844
Martínez-Muriana A, Mancuso R, Francos-Quijorna I, Olmos-Alonso A, Osta R, Perry VH, Navarro X, Gomez-Nicola D, López-Vales R (2016) CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci Rep 6:25663. https://doi.org/10.1038/srep25663
Marzan DE, Brügger-Verdon V, West BL, Liddelow S, Samanta J, Salzer JL (2021) Activated microglia drive demyelination via CSF1R signaling. Glia 69:1583–1604. https://doi.org/10.1002/glia.23980
Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27:1918–1929. https://doi.org/10.1111/ene.14393
M.D. Anderson Cancer Center (2020) A Pilot presurgical study of daratumumab (CD38 Antagonist) or JNJ-40346527 in men with high-risk localized prostate cancer followed by radical prostatectomy (Clinical trial registration No. NCT03177460). clinicaltrials.gov
Merry TL, Brooks AES, Masson SW, Adams SE, Jaiswal JK, Jamieson SMF, Shepherd PR (2020) The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice. Int J Obes 44:245–253. https://doi.org/10.1038/s41366-019-0355-7
Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A (2010) Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Bioorg Med Chem Lett 20:1543–1547. https://doi.org/10.1016/j.bmcl.2010.01.078
Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch U-K, Mack M, Heikenwalder M, Brück W, Priller J, Prinz M (2007) Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 10:1544–1553. https://doi.org/10.1038/nn2015
Mitrasinovic OM, Perez GV, Zhao F, Lee YL, Poon C, Murphy GM (2001) Overexpression of macrophage colony-stimulating factor receptor on microglial cells induces an inflammatory response. J Biol Chem 276:30142–30149
Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz J-F, Moussy A, Kinet J-P, Hermine O, Rougier P, Raymond E (2010) Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 66:395–403. https://doi.org/10.1007/s00280-010-1299-8
Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, Marín S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet J-P, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O (2020) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Front Degener 21:5–14. https://doi.org/10.1080/21678421.2019.1632346
Munugalavadla V, Borneo J, Ingram DA, Kapur R (2005) p85α subunit of class IA PI-3 kinase is crucial for macrophage growth and migration. Blood 106:103–109
Murase S, Hayashi Y (1998) Expression pattern and neurotrophic role of the c-fms proto-oncogene M-CSF receptor in rodent Purkinje cells. J Neurosci 18:10481–10492
Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Cytokines in Parkinson’s disease. J Neural Transm Suppl 58:143–151
Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin L-W, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43:436–441. https://doi.org/10.1038/ng.801
Nakamichi Y, Udagawa N, Takahashi N (2013) IL-34 and CSF-1: similarities and differences. J Bone Miner Metab 31:486–495
Nandi S, Gokhan S, Dai X-M, Wei S, Enikolopov G, Lin H, Mehler MF, Stanley ER (2012) The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol 367:100–113
Neal M, Richardson JR (2018) Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration. Biochim Biophys Acta Mol Basis Dis 1864:432–443. https://doi.org/10.1016/j.bbadis.2017.11.004
Neal ML, Fleming SM, Budge KM, Boyle AM, Kim C, Alam G, Beier EE, Wu L-J, Richardson JR (2020) Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration. FASEB J 34:1679–1694. https://doi.org/10.1096/fj.201900567RR
Nishiyama C, Nishiyama M, Ito T, Masaki S, Masuoka N, Yamane H, Kitamura T, Ogawa H, Okumura K (2004) Functional analysis of PU.1 domains in monocyte-specific gene regulation. FEBS Lett 561:63–68. https://doi.org/10.1016/S0014-5793(04)00116-4
Nissen JC, Thompson KK, West BL, Tsirka SE (2018) Csf1R inhibition attenuates experimental autoimmune encephalomyelitis and promotes recovery. Exp Neurol 307:24–36. https://doi.org/10.1016/j.expneurol.2018.05.021
Nortje J, Menon DK (2004) Traumatic brain injury: physiology, mechanisms, and outcome. Curr Opin Neurol 17:711–718. https://doi.org/10.1097/00019052-200412000-00011
Novartis Pharmaceuticals (2021a) A Phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination With PDR001 in adults patients with advanced solid tumors (Clinical trial registration No. NCT02829723). clinicaltrials.gov
Novartis Pharmaceuticals (2021b) An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following multiple doses of BLZ945 Using positron emission tomography (PET) with the radioligand [11C]-PBR28 (Clinical trial registration No. NCT04066244). clinicaltrials.gov
Nylander A, Hafler DA (2012) Multiple sclerosis. J Clin Invest 122:1180–1188. https://doi.org/10.1172/JCI58649
Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D, Gross CT (2011) Synaptic pruning by microglia is necessary for normal brain development. Science 333:1456–1458. https://doi.org/10.1126/science.1202529
Paschalis EI, Lei F, Zhou C, Kapoulea V, Dana R, Chodosh J, Vavvas DG, Dohlman CH (2018a) Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes. Proc Natl Acad Sci 115:E11359–E11368. https://doi.org/10.1073/pnas.1807123115
Paschalis EI, Lei F, Zhou C, Kapoulea V, Thanos A, Dana R, Vavvas DG, Chodosh J, Dohlman CH (2018b) The role of microglia and peripheral monocytes in retinal damage after corneal chemical injury. Am J Pathol 188:1580–1596. https://doi.org/10.1016/j.ajpath.2018.03.005
Pascual O, Achour SB, Rostaing P, Triller A, Bessis A (2012) Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci 109:E197–E205. https://doi.org/10.1073/pnas.1111098109
Peng B, Xiao J, Wang K, So K-F, Tipoe GL, Lin B (2014) Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. J Neurosci 34:8139–8150. https://doi.org/10.1523/JNEUROSCI.5200-13.2014
Pixley FJ (2012) Macrophage migration and its regulation by CSF-1. Int J Cell Biol. https://doi.org/10.1155/2012/501962
Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M (2015) TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest 125:2161–2170. https://doi.org/10.1172/JCI77983
Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL (2011) MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α–PU.1 pathway. Nat Med 17:64–70. https://doi.org/10.1038/nm.2266
Pons V, Lévesque P, Plante M-M, Rivest S (2021) Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer’s disease. Alzheimers Res Ther 13:8. https://doi.org/10.1186/s13195-020-00747-7
Pridans C, Sauter KA, Baer K, Kissel H, Hume DA (2013) CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function. Sci Rep 3:3013
Prinz M, Mildner A (2011) Microglia in the CNS: immigrants from another world. Glia 59:177–187. https://doi.org/10.1002/glia.21104
Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:1264–1272. https://doi.org/10.1038/nm.3337
Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC, Joyce JA (2016) The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352:aad3018. https://doi.org/10.1126/science.aad3018
Rappold PM, Tieu K (2010) Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics 7:413–423. https://doi.org/10.1016/j.nurt.2010.07.001
Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease, 2020. . AB Sci. URL https://www.ab-science.com/results-from-phase-2b-3-study-evaluating-masitinib-in-alzheimers-disease/. Accessed 22 Aug 2021
Rice RA, Pham J, Lee RJ, Najafi AR, West BL, Green KN (2017) Microglial repopulation resolves inflammation and promotes brain recovery after injury. Glia 65:931–944. https://doi.org/10.1002/glia.23135
Rice RA, Spangenberg EE, Yamate-Morgan H, Lee RJ, Arora RPS, Hernandez MX, Tenner AJ, West BL, Green KN (2015) Elimination of microglia improves functional outcomes following extensive neuronal loss in the hippocampus. J Neurosci 35:9977–9989. https://doi.org/10.1523/JNEUROSCI.0336-15.2015
Ridley AJ (2008) Regulation of macrophage adhesion and migration by Rho GTP-binding proteins. J Microsc 231:518–523. https://doi.org/10.1111/j.1365-2818.2008.02064.x
Rohde CM, Schrum J, Lee AW-M (2004) A juxtamembrane tyrosine in the colony stimulating factor-1 receptor regulates ligand-induced Src association, receptor kinase function, and down-regulation. J Biol Chem 279:43448–43461
Roozenbeek B, Maas AIR, Menon DK (2013) Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol 9:231–236. https://doi.org/10.1038/nrneurol.2013.22
Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33:119–126. https://doi.org/10.1016/j.it.2011.12.001
Salter MW, Stevens B (2017) Microglia emerge as central players in brain disease. Nat Med 23:1018–1027. https://doi.org/10.1038/nm.4397
Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41:1303–1307. https://doi.org/10.1038/ng.485
Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B (2012) Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74:691–705. https://doi.org/10.1016/j.neuron.2012.03.026
Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SEW, Pollard JW, Frampton J, Liu KJ, Geissmann F (2012) A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336:86–90. https://doi.org/10.1126/science.1219179
Schwartz SD, Pan CK, Klimanskaya I, Lanza R (2014) Chapter 68 - retinal degeneration. In: Lanza R, Langer R, Vacanti J (eds) Principles of tissue engineering, 4th edn. Academic Press, Boston, pp 1427–1440
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608
Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER (1985) The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1. Cell 41:665–676
Shinozaki Y, Shibata K, Yoshida K, Shigetomi E, Gachet C, Ikenaka K, Tanaka KF, Koizumi S (2017) Transformation of astrocytes to a neuroprotective phenotype by microglia via P2Y1 receptor downregulation. Cell Rep 19:1151–1164. https://doi.org/10.1016/j.celrep.2017.04.047
Silverman SM, Wong WT (2018) Microglia in the retina: roles in development, maturity, and disease. Annu Rev vis Sci 4:45–77. https://doi.org/10.1146/annurev-vision-091517-034425
Simon DW, McGeachy MJ, Bayır H, Clark RSB, Loane DJ, Kochanek PM (2017) The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol 13:572. https://doi.org/10.1038/nrneurol.2017.116
Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41:1308–1312. https://doi.org/10.1038/ng.487
Son Y, Jeong YJ, Shin N-R, Oh SJ, Nam KR, Choi H-D, Choi JY, Lee H-J (2020) Inhibition of colony-stimulating factor 1 receptor by PLX3397 prevents amyloid beta pathology and rescues dopaminergic signaling in aging 5xFAD mice. Int J Mol Sci 21:E5553. https://doi.org/10.3390/ijms21155553
Song H, Stevens CF, Gage FH (2002) Astroglia induce neurogenesis from adult neural stem cells. Nature 417:39–44. https://doi.org/10.1038/417039a
Soto F, Kerschensteiner D (2015) Synaptic remodeling of neuronal circuits in early retinal degeneration. Front Cell Neurosci 9:395. https://doi.org/10.3389/fncel.2015.00395
Soto-Diaz K, Vailati-Riboni M, Louie AY, McKim DB, Gaskins HR, Johnson RW, Steelman AJ (2021) Treatment with the CSF1R antagonist GW2580, sensitizes microglia to reactive oxygen species. Front Immunol 12:734349. https://doi.org/10.3389/fimmu.2021.734349
Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, Habets G, Rymar A, Tsang G, Walters J, Nespi M, Singh P, Broome S, Ibrahim P, Zhang C, Bollag G, West BL, Green KN (2019) Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun 10:3758. https://doi.org/10.1038/s41467-019-11674-z
Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MRP, Blurton-Jones M, West BL, Green KN (2016) Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-β pathology. Brain J Neurol 139:1265–1281. https://doi.org/10.1093/brain/aww016
Spiller KJ, Restrepo CR, Khan T, Dominique MA, Fang TC, Canter RG, Roberts CJ, Miller KR, Ransohoff RM, Trojanowski JQ, Lee VM-Y (2018) Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat Neurosci 21:329–340. https://doi.org/10.1038/s41593-018-0083-7
Stafford JH, Hirai T, Deng L, Chernikova SB, Urata K, West BL, Brown JM (2016) Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro-Oncol 18:797–806. https://doi.org/10.1093/neuonc/nov272
Stanley ER, Chitu V (2014) CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol 6:a021857
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson’s Disease. Neurobiol Aging 29:1690–1701. https://doi.org/10.1016/j.neurobiolaging.2007.04.006
Tahmasebi F, Pasbakhsh P, Mortezaee K, Madadi S, Barati S, Kashani IR (2019) Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model. J Cell Biochem 120:10576–10586. https://doi.org/10.1002/jcb.28344
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay J-Y, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ, ENLIVEN Investigators (2019) Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet Lond. Engl. 394:478–487. https://doi.org/10.1016/S0140-6736(19)30764-0
Tarale P, Chakrabarti T, Sivanesan S, Naoghare P, Bafana A, Krishnamurthi K (2016) Potential role of epigenetic mechanism in manganese induced neurotoxicity. BioMed Res Int 2016:2548792. https://doi.org/10.1155/2016/2548792
Tarale P, Daiwile AP, Sivanesan S, Stöger R, Bafana A, Naoghare PK, Parmar D, Chakrabarti T, Krishnamurthi K (2018) Manganese exposure: Linking down-regulation of miRNA-7 and miRNA-433 with α-synuclein overexpression and risk of idiopathic Parkinson’s disease. Toxicol Vitro Int J Publ Assoc BIBRA 46:94–101. https://doi.org/10.1016/j.tiv.2017.10.003
Tarale P, Naoghare P, Tagde J, Bafana A, Sivanesan S (2020) Diverse cancer therapeutic interactions: complexities in cancer management. Pharmacother Bot Cancer Chemoprevention. https://doi.org/10.1007/978-981-15-5999-0_3
Tarale P, Sivanesan S, Daiwile AP, Stöger R, Bafana A, Naoghare PK, Parmar D, Chakrabarti T, Kannan K (2017) Global DNA methylation profiling of manganese-exposed human neuroblastoma SH-SY5Y cells reveals epigenetic alterations in Parkinson’s disease-associated genes. Arch Toxicol 91:2629–2641. https://doi.org/10.1007/s00204-016-1899-0
Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SAS, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OMA (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766–1772. https://doi.org/10.1212/WNL.0b013e3181fd613b
Trias E, Ibarburu S, Barreto-Núñez R, Babdor J, Maciel TT, Guillo M, Gros L, Dubreuil P, Díaz-Amarilla P, Cassina P, Martínez-Palma L, Moura IC, Beckman JS, Hermine O, Barbeito L (2016) Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation 13:177. https://doi.org/10.1186/s12974-016-0620-9
Tushinski RJ, Stanley ER (1985) The regulation of mononuclear phagocyte entry into S phase by the colony stimulating factor CSF-1. J Cell Physiol 122:221–228
Tushinski RJ, Stanley ER (1983) The regulation of macrophage protein turnover by a colony stimulating factor (CSF-1). J Cell Physiol 116:67–75
Unger MS, Schernthaner P, Marschallinger J, Mrowetz H, Aigner L (2018) Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice. J Neuroinflammation 15:274. https://doi.org/10.1186/s12974-018-1304-4
University of Oxford (2020) A randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the colony stimulating factor-1 (CSF-1) receptor antagonist JNJ-40346527 in participants with mild cognitive impairment (Clinical trial registration No. NCT04121208). clinicaltrials.gov
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabrie S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17:98. https://doi.org/10.1016/j.ccr.2009.12.020
Vincent VAM, Robinson CC, Simsek D, Murphy GM (2002) Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures. J Neurochem 82:1388–1397. https://doi.org/10.1046/j.1471-4159.2002.01087.x
von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S, Aquino R, Kotoulek S, de Boer CJ, Engert A (2015) An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory hodgkin lymphoma. Clin Cancer Res 21:1843–1850. https://doi.org/10.1158/1078-0432.CCR-14-1845
Walker DG, Tang TM, Lue L-F (2017) Studies on colony stimulating factor receptor-1 and ligands colony stimulating factor-1 and interleukin-34 in Alzheimer’s disease brains and human microglia. Front Aging Neurosci 9:244
Walter M, Lucet IS, Patel O, Broughton SE, Bamert R, Williams NK, Fantino E, Wilks AF, Rossjohn J (2007) The 2.7 \AA crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 367:839–847
Walton MR, Gibbons H, MacGibbon GA, Sirimanne E, Saura J, Gluckman PD, Dragunow M (2000) PU.1 expression in microglia. J Neuroimmunol 104:109–115. https://doi.org/10.1016/s0165-5728(99)00262-3
Wang Y, Berezovska O, Fedoroff S (1999) Expression of colony stimulating factor-1 receptor (CSF-1R) by CNS neurons in mice. J Neurosci Res 57:616–632
Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M (2012) IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol 13:753–760. https://doi.org/10.1038/ni.2360
Whitton PS (2010) Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson’s disease. Curr Opin Investig Drugs Lond Engl 2000(11):788–794
Wies Mancini VSB, Pasquini JM, Correale JD, Pasquini LA (2019) Microglial modulation through colony-stimulating factor-1 receptor inhibition attenuates demyelination. Glia 67:291–308. https://doi.org/10.1002/glia.23540
Witcher KG, Bray CE, Chunchai T, Zhao F, O’Neil SM, Gordillo AJ, Campbell WA, McKim DB, Liu X, Dziabis JE, Quan N, Eiferman DS, Fischer AJ, Kokiko-Cochran ON, Askwith C, Godbout JP (2021) Traumatic brain injury causes chronic cortical inflammation and neuronal dysfunction mediated by microglia. J Neurosci 41:1597–1616. https://doi.org/10.1523/JNEUROSCI.2469-20.2020
Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36:422–439. https://doi.org/10.1016/j.tips.2015.04.005
Xie Z, Wu B, Liu Y, Ren W, Tong L, Xiang C, Wei A, Gao Y, Zeng L, Xie H, Tang W, Hu Y (2020) Novel class of colony-stimulating factor 1 receptor kinase inhibitors based on an o-aminopyridyl alkynyl scaffold as potential treatment for inflammatory disorders. J Med Chem 63:1397–1414. https://doi.org/10.1021/acs.jmedchem.9b01912
Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL, Joyce JA (2017) Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene 36:6049–6058. https://doi.org/10.1038/onc.2017.261
Yang X, Ren H, Wood K, Li M, Qiu S, Shi F-D, Ma C, Liu Q (2018) Depletion of microglia augments the dopaminergic neurotoxicity of MPTP. FASEB J 32:3336–3345. https://doi.org/10.1096/fj.201700833RR
Yeung YG, Jubinsky PT, Sengupta A, Yeung Dc, Stanley ER (1987) Purification of the colony-stimulating factor 1 receptor and demonstration of its tyrosine kinase activity. Proc Natl Acad Sci 84:1268–1271
Yu C-H, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, Louis C, Low RRJ, Moecking J, De Nardo D, Balka KR, Calleja DJ, Moghaddas F, Ni E, McLean CA, Samson AL, Tyebji S, Tonkin CJ, Bye CR, Turner BJ, Pepin G, Gantier MP, Rogers KL, McArthur K, Crouch PJ, Masters SL (2020) TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell 183:636-649.e18. https://doi.org/10.1016/j.cell.2020.09.020
Yu W, Chen J, Xiong Y, Pixley FJ, Dai X-M, Yeung Y-G, Stanley ER (2008) CSF-1 receptor structure/function in MacCsf1r-/- macrophages: regulation of proliferation, differentiation, and morphology. J Leukoc Biol 84:852–863. https://doi.org/10.1189/jlb.0308171
Yu W, Chen J, Xiong Y, Pixley FJ, Yeung Y-G, Stanley ER (2012) Macrophage proliferation is regulated through CSF-1 receptor tyrosines 544, 559, and 807. J Biol Chem 287:13694–13704
Zabel MK, Zhao L, Zhang Y, Gonzalez SR, Ma W, Wang X, Fariss RN, Wong WT (2016) Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa. Glia 64:1479–1491. https://doi.org/10.1002/glia.23016
Zendedel A, Beyer C, Kipp M (2013) Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci MN 51:567–572. https://doi.org/10.1007/s12031-013-0026-4
Zhang Q-S, Heng Y, Yuan Y-H, Chen N-H (2017) Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation. Toxicol Lett 265:30–37
Acknowledgements
The authors are thankful to Dr. Arthi Kanthasamy, Professor, Biomedical Science, Iowa State University, Ames Iowa for her valuable suggestions on writing and insightful on topic of review manuscript.
Author information
Authors and Affiliations
Contributions
Conceptualization: PT; Writing—original draft, review & editing: PT, MMA; Writing -review & editing: PT, MMA; Art-work: PT.
Corresponding author
Ethics declarations
Conflict of interest
The authors declares that there is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tarale, P., Alam, M.M. Colony-stimulating factor 1 receptor signaling in the central nervous system and the potential of its pharmacological inhibitors to halt the progression of neurological disorders. Inflammopharmacol 30, 821–842 (2022). https://doi.org/10.1007/s10787-022-00958-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-022-00958-4